Tenderwize
Wróć do wyszukiwania

Non-exclusive Drug Discount Agreement for Liraglutid

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jun 30, 2027 · 307 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Liraglutid (ATC-Code nach WHO: A10BJ02; amtlicher ATC: A10BJ02)

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

20 / 100

Czynniki ryzyka

No minimum purchase quantities; actual demand depends on unpredictable factors (prescriptions, pharmacy behavior). Reve...

Buyer reserves the right to terminate the open-house process early if exclusive agreements are concluded (typical 8-12...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Conclusion of non-exclusive discount agreements for the supply of Liraglutid (ATC A10BJ02) to the AOK PLUS health insurance.
  • Open-house model: all qualified pharmaceutical companies can participate at any time during the participation period.
Pokaż pełne podsumowanie

Non-exclusive drug discount agreement for the active substance Liraglutid (ATC A10BJ02) under German social law (§ 130a Abs. 8 SGB V), using an open-house model. The agreement is open to all qualified pharmaceutical companies, with no exclusivity. No estimated value or guaranteed purchase quantities are provided. The agreement ends on 30 June 2027.

Ryzyka

No minimum purchase quantities; actual demand depends on unpredictable factors (prescriptions, pharmacy behavior). Reve...

Buyer reserves the right to terminate the open-house process early if exclusive agreements are concluded (typical 8-12...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical company as defined in § 4 Abs. 18 AMG with respect to the offered product.
  • Company seat must be in Germany, EU, or EEA.

Eligibility

  • Submit required declarations (exclusion grounds, Russia sanctions).

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No explicit award criteria described; likely based on the offered discount percentage.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Liraglutid

Open-house model for concluding non-exclusive discount agreements on pharmaceuticals containing Liraglutid (ATC A10BJ02). No guaranteed volumes, no exclusivity. Multiple submissions possible during the participation period.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Jun 2026 - Jun 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No explicit award criteria described; likely based on the offered discount percentage.

Termin

Deadline Jun 30, 2027

Szczegóły zamówienia

Data publikacji
05 May 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
309108-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3